Table 1.

Summary of case reports with antifibrinolytics in cirrhosis‐related bleeding

Authors	Number of patients	Age/sex	Presentation/indication	Treatment type/dosing	Outcome
Gunawan et al15	52	Mean age 49.6 y (32‐67) Males, 73%	Study included 37 bleeding patients and 15 patients with no bleeding but shortened euglobulin clot lysis time	EACA‐1 g q6h	37 bleeding patients—34 had resolution of bleeding, 2 patients with no improvement, 1 patient died 15 patients without bleeding—14 did well with no bleeding episodes, 1 had melena and died from liver failure complications
Nair et al16	1	65/male	Cirrhosis with spontaneous intramuscular hematoma	EACA 150 mg/kg loading dose followed by 1 g q4h × 2	Resolution of bleeding
Laskiewicz et al17	1	72/male	Advanced cirrhosis with bleeding	TXA 1000 mg intravenous bolus followed by 1000 mg IV over 8 h on days 16, 18, and 23	Expired on day 23 from pulseless electrical activity
Louro et al18	1	69/male	Bleeding from blunt abdominal trauma	Factor VIIa 1 mg and TXA 1 g i.v. bolus	Expired from multiorgan failure

Abbreviations: EACA: ε‐aminocaproic acid; TXA; tranexamic acid.